[Concurrent therapy of osteoporosis].
We investigated the efficacy of concurrent use of two of 1alphaOH vitamin D(3), vitamin K(2), and EHDP in increasing lumbar BMD and in preventing new fracture in patients with primary osteoporosis. D(3) + K(2) showed little effect and was considered to be poor combination. EHDP + D(3) or EHDP + K(2) was superior to single use of these agents in both end points. Concurrent use of anti-osteoporosis agents could be advantageous in some combination but not in another. We need more clinical data on concurrent therapy of osteoporosis.